Inclusion Criteria:  Provision of informed consent prior to any study specific procedures; Established indication to PPCI according to the guidelines of American Heart Association and American College of Cardiology; Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) with MVD after successful revascularization of the culprit artery; De novo coronary lesion, TIMI Flow 3 ( Cases with TIMI flow 2 need to perform angiographic again in 24h ensured TIMI flow 3 for enrolling case )after revascularization of the culprit artery, residual stenosis ≤20% and no coronary dissection greater than or equal to type C leading to (threatening) vessel closure. At least one non-culprit coronary stenosis ≥ 80% and accompanied by QFR ≤0.8 in a vessel with a lumen diameter ≥2.5;  Exclusion Criteria:  Age <18 yr and >80 yr; Cardiac shock, multiple organ failure, cerebral hemorrhage, severe aortic stenosis and myocardial infarction complications(cardiac rupture, ventricular septal rupture and papillary muscle rupture); Killip classification >3, cardiognic shock, shore-infarction of culprit artery after emergency PCI in 24 hours; Previous documented allergic reaction to drug and device of this study; Planned major surgery within 6 weeks in which impact DAPT; Participation in another clinical study, interfering with this protocol Uncertain; Life expectancy < 1 year; Any condition likely to interfere with study processes including follow-up visits or increase of risk accessed by researcher.